Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at MPS VI- patienter fik gavnlig virkning af behandling med Naglazyme så som forbedret bevægelsesevne sammenlignet med placebo - behandlede patienter.
The Committee for Medicinal Products for Human Use (CHMP) decided that for patients with MPS VI, treatment with Naglazyme provides benefits such as improved mobility when compared with patients given placebo.